Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 9/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.36 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17193999 | 0.86 | PGR (0.44) | PGRCA1CA2PDE3A | |
| SCHEMBL17193998 | 0.81 | SLC5A1 (0.37) | PGRKMT2ASLC5A1SLC5A2KDM1A | |
| SCHEMBL18469490 | 0.78 | KMT2A (0.34) | PGRKMT2ASLC5A1SLC5A2KDM1A | |
| SCHEMBL18474170 | 0.78 | KMT2A (0.34) | PGRKMT2ASLC5A1SLC5A2KDM1A | |
| SCHEMBL16172610 | 0.78 | SLC5A1 (0.34) | PGRKMT2ASLC5A1SLC5A2 | |
| SCHEMBL23463196 | 0.76 | PGR (0.33) | PGR | |
| SCHEMBL30648842 | 0.76 | KDM1A (0.36) | PGRKDM1A | |
| SCHEMBL309789 | 0.76 | KDM1A (0.36) | PGRKDM1A | |
| SCHEMBL30648685 | 0.76 | CA9 (0.38) | PGRKMT2ACA1CA2 | |
| SCHEMBL9727613 | 0.76 | OPRM1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170333426-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives And Their Use For The Treatment Of Prevention Of Neurological And Psychiatric Disorders | JANSSEN PHARMACEUTICALS INC (US) | 2017-11-23 | — | — | US | disclosed |
| US-9737533-B2 | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders | Janssen Pharmaceuticals. Inc. (US) | 2017-08-22 | — | — | US | disclosed |
| EP-3133071-A1 | C-ARYL INDICAN DERIVATIVE, AND PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR AND USES THEREOF | Shanghai De Novo Pharmatech Co Ltd. (CN) | 2017-02-22 | — | — | EP | disclosed |
| US-20170037038-A1 | C- ARYL GLYCOSID DERIVATIVES, PHARMACEUTICAL COMPOSITION, PREPARATION PROCESS AND USES THEREOF | SHANGHAI DE NOVO PHARMATECH CO. LTD. (CN) | 2017-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037038-A1 | C- ARYL GLYCOSID DERIVATIVES, PHARMACEUTICAL COMPOSITION, PREPARATION PROCESS AND USES THEREOF | SLC5A2, SLC5A1, MGAT1 | PGR 3361/4885KMT2A 873/4885SLC5A1 2/4885 |
| US-20170333426-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives And Their Use For The Treatment Of Prevention Of Neurological And Psychiatric Disorders | GRM2, GRM1, GRIN2C | PGR 1014/4885KMT2A 988/4885SLC5A1 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.